Search

Your search keyword '"squamous non-small-cell lung cancer"' showing total 4 results
Start Over Descriptor "squamous non-small-cell lung cancer" Topic antineoplastic combined chemotherapy protocols
4 results on '"squamous non-small-cell lung cancer"'

1. A Phase II Study of Cisplatin Plus Gemcitabine followed by Maintenance Gemcitabine for Advanced Squamous Non-Small-Cell Lung Cancer: Kyoto Thoracic Oncology Research Group 1302.

Author

Ikeda S, Yoshioka H, Kaneda T, Yokoyama T, Niwa T, Sone N, Ishida T, Morita M, Tomioka H, Komaki C, Hirabayashi M, Hasegawa Y, Noguchi T, Nakano Y, Sakaguchi C, Yoshimura K, and Hirai T

Subjects
Aged, Carcinoma, Non-Small-Cell Lung mortality, Cisplatin administration & dosage, Cisplatin adverse effects, Deoxycytidine administration & dosage, Deoxycytidine adverse effects, Deoxycytidine analogs & derivatives, Humans, Lung Neoplasms mortality, Male, Middle Aged, Gemcitabine, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Carcinoma, Non-Small-Cell Lung drug therapy, Lung Neoplasms drug therapy
Abstract

Background: There has been no study so far on gemcitabine continuous maintenance therapy targeting only squamous non-small-cell lung cancer (NSCLC) patients. This study aimed to assess the efficacy and safety of cisplatin plus gemcitabine followed by maintenance gemcitabine for chemotherapy- naïve Japanese patients with advanced squamous NSCLC., Methods: The patients received 4 cycles of gemcitabine (1,000 mg/m2, days 1 and 8) and cisplatin (80 mg/m2, day 1) every 3 weeks, followed by gemcitabine alone as maintenance therapy every 3 weeks until disease progression or unacceptable toxicity. The primary end point of the study was progression-free survival (PFS) from the date of registration., Results: From May 2013 to October 2018, 26 patients were enrolled, and 25 patients received ≥1 cycle of planned treatment. Eighteen patients (69.2%) received 4 cycles of cisplatin plus gemcitabine, and 16 patients (61.5%) received ≥1 cycle of maintenance gemcitabine. The median PFS from the date of registration was 5.3 months (95% CI 2.9-7.3 months). In 16 patients who received ≥1 cycle of maintenance gemcitabine, the median PFS from the date of maintenance gemcitabine initiation was 3.8 months (95% CI 2.3-5.2 months). Their median overall survival from the date of registration was 11.9 months (95% CI 7.5-26.5 months). During the maintenance therapy, adverse events (AEs) were mostly Common Terminology Criteria for AE grade 1., Conclusions: While this trial did not meet the primary endpoint, the sufficient efficacy and feasibility of gemcitabine maintenance therapy were suggested., (© 2019 S. Karger AG, Basel.)

Published
2019
Full Text
View/download PDF

2. A randomized trial of TLR-2 agonist CADI-05 targeting desmocollin-3 for advanced non-small-cell lung cancer.

Author

Belani CP, Chakraborty BC, Modi RI, and Khamar BM

Subjects
Adenocarcinoma mortality, Adenocarcinoma pathology, Adult, Aged, Aged, 80 and over, Bacterial Vaccines administration & dosage, Carcinoma, Non-Small-Cell Lung mortality, Carcinoma, Non-Small-Cell Lung pathology, Carcinoma, Squamous Cell mortality, Carcinoma, Squamous Cell pathology, Cisplatin administration & dosage, Desmocollins antagonists & inhibitors, Disease-Free Survival, Female, Humans, Kaplan-Meier Estimate, Lung Neoplasms mortality, Lung Neoplasms pathology, Male, Middle Aged, Paclitaxel administration & dosage, Proportional Hazards Models, Toll-Like Receptor 2 agonists, Treatment Outcome, Adenocarcinoma drug therapy, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Squamous Cell drug therapy, Lung Neoplasms drug therapy
Abstract

Background: Randomized controlled trial to evaluate synergy between taxane plus platinum chemotherapy and CADI-05, a Toll like receptor-2 agonist targeting desmocollin-3 as a first-line therapy in advanced non-small-cell lung cancer (NSCLC)., Patients and Methods: Patients with advanced NSCLC (stage IIIB or IV) were randomized to cisplatin-paclitaxel (chemotherapy group, N = 112) or cisplatin-paclitaxel plus CADI-05 (chemoimmunotherapy group, N = 109). CADI-05 was administered a week before chemotherapy and on days 8 and 15 of each cycle and every month subsequently for 12 months or disease progression. Overall survival was compared using a log-rank test. Computed tomography was carried out at baseline, end of two cycles and four cycles. Response rate was evaluated using Response Evaluation Criteria in Solid Tumors criteria by an independent radiologist., Results: As per intention-to-treat analysis, no survival benefit was observed between two groups [208 versus 196 days; hazard ratio, 0.86; 95% confidence interval (CI) 0.63-1.19; P = 0.3804]. In a subgroup analysis, improvement in median survival by 127 days was observed in squamous NSCC with chemoimmunotherapy (hazard ratio, 0.55; 95% CI 0.32-0.95; P = 0.046). In patients receiving planned four cycles of chemotherapy, there was improved median overall survival by 66 days (299 versus 233 days; hazard ratio, 0.64; 95% CI 0.41 to 0.98; P = 0.04) in the chemoimmunotherapy group compared with the chemotherapy group. This was associated with the improved survival by 17.48% at the end of 1 year, in the chemoimmunotherapy group. Systemic adverse events were identical in both the groups., Conclusion: There was no survival benefit with the addition of CADI-05 to the combination of cisplatin-paclitaxel in patients with advanced NSCLC; however, the squamous cell subset did demonstrate a survival advantage., (© The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For Permissions, please email: journals.permissions@oup.com.)

Published
2017
Full Text
View/download PDF

3. A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407

Author

Jerónimo Rodríguez-Cid, Ying Cheng, Irfan Cicin, Balazs Halmos, Sung Sook Lee, Barbara Hermes, David Vicente, Rodryg Ramlau, Bilal Piperdi, Ying Zhang, Tuba Bas, Hector Soto Parra, Luis Paz-Ares, Vladimir Vladimirov, Xuan Deng, Isamu Okamoto, Ali Tafreshi, Andrew G. Robinson, Julien Mazieres, and Balazs Medgyasszay

Subjects
0301 basic medicine, Pulmonary and Respiratory Medicine, Oncology, PD-L1, medicine.medical_specialty, Lung Neoplasms, medicine.medical_treatment, Placebo-controlled study, Pembrolizumab, Placebo, Antibodies, Monoclonal, Humanized, Antibodies, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Internal medicine, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, medicine, Chemotherapy, Humans, Humanized, Squamous non–small-cell lung cancer, business.industry, Carcinoma, Hazard ratio, medicine.disease, Interim analysis, Carboplatin, 030104 developmental biology, Squamous Cell, chemistry, 030220 oncology & carcinogenesis, Carcinoma, Squamous Cell, business, Progressive disease
Abstract

Introduction In the randomized KEYNOTE-407 study ( ClinicalTrials.gov , NCT02775435 ), pembrolizumab plus carboplatin and paclitaxel/nab-paclitaxel (chemotherapy) significantly improved overall survival (OS) and progression-free survival (PFS) compared with placebo plus chemotherapy in patients with previously untreated metastatic squamous NSCLC. We report updated efficacy outcomes from the protocol-specified final analysis and, for the first time, progression on next line of treatment. Methods Eligible patients were randomized to chemotherapy plus either pembrolizumab (n = 278) or placebo (n = 281). After positive results from the second interim analysis, patients still receiving placebo could cross over to pembrolizumab monotherapy at the time of confirmed progressive disease. The primary end points were OS and PFS. PFS-2 (time from randomization to progression on next-line treatment/death, whichever occurred first) was an exploratory end point. Results After median (range) follow-up of 14.3 (0.1–31.3) months, pembrolizumab plus chemotherapy continued to exhibit a clinically meaningful improvement over placebo plus chemotherapy in OS (median, 17.1 mo [95% confidence interval (CI): 14.4‒19.9] versus 11.6 mo [95% CI: 10.1‒13.7]; hazard ratio [HR], 0.71 [95% CI: 0.58‒0.88]) and PFS (median, 8.0 mo [95% CI: 6.3‒8.4] versus 5.1 mo [95% CI: 4.3‒6.0]; HR, 0.57 [95% CI: 0.47‒0.69]). PFS-2 was longer for patients randomized to first-line pembrolizumab plus chemotherapy (HR, 0.59 [95% CI: 0.49‒0.72]). Grade 3 to 5 adverse events occurred in 74.1% and 69.6% of patients receiving pembrolizumab plus chemotherapy and placebo plus chemotherapy, respectively. Conclusions Pembrolizumab plus chemotherapy continued to exhibit substantially improved OS and PFS in patients with metastatic squamous NSCLC. The PFS-2 outcomes support pembrolizumab plus chemotherapy as a standard first-line treatment in patients with metastatic squamous NSCLC.

Published
2020

4. Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer

Author

J.S. de Bono, Joseph R. Evans, Wolfram Brugger, Susana Carreira, Matthew G Krebs, Elizabeth A. Harrington, Ruth Ruddle, Beth Purchase, Robert H. Jones, Mahesh K. B. Parmar, Alison Turner, Karen E Swales, Udai Banerji, F.M. de Oliveira, Michael Brada, Holly Tovey, Bristi Basu, Emma Hall, Richard H. Wilson, Susana Banerjee, J.C. Dawes, Florence I. Raynaud, Nina Tunariu, James Spicer, N. Steele, Denis Talbot, A.H. Ingles Garces, Raghav Sundar, Basu, Bristi [0000-0002-3562-2868], and Apollo - University of Cambridge Repository

Subjects
0301 basic medicine, Male, Lung Neoplasms, medicine.medical_treatment, m-TORC1/m-TORC2 inhibitor, Phases of clinical research, Gastroenterology, combination therapy, chemistry.chemical_compound, 0302 clinical medicine, Carcinoma, Non-Small-Cell Lung, Antineoplastic Combined Chemotherapy Protocols, squamous non-small cell lung cancer, Phosphorylation, Ovarian Neoplasms, Manchester Cancer Research Centre, Hematology, Middle Aged, squamous non-small-cell lung cancer, ovarian cancer, Oncology, Paclitaxel, Response Evaluation Criteria in Solid Tumors, 030220 oncology & carcinogenesis, Benzamides, Early Drug Development, Female, Adult, medicine.medical_specialty, Maximum Tolerated Dose, Morpholines, Mechanistic Target of Rapamycin Complex 2, Mechanistic Target of Rapamycin Complex 1, Drug Administration Schedule, 03 medical and health sciences, Internal medicine, medicine, Mucositis, Humans, Progression-free survival, Lung cancer, Protein Kinase Inhibitors, Chemotherapy, business.industry, Ribosomal Protein S6 Kinases, ResearchInstitutes_Networks_Beacons/mcrc, Original Articles, medicine.disease, 030104 developmental biology, Pyrimidines, chemistry, phase 1, Ovarian cancer, business
Abstract

Background: \ud We have previously shown that raised p-S6K levels correlate with resistance to chemotherapy in ovarian cancer. We hypothesised that inhibiting p-S6K signalling with the dual m-TORC1/2 inhibitor in patients receiving weekly paclitaxel could improve outcomes in such patients.\ud \ud Patients and methods: \ud In dose escalation, weekly paclitaxel (80 mg/m2) was given 6/7 weeks in combination with two intermittent schedules of vistusertib (dosing starting on the day of paclitaxel): schedule A, vistusertib dosed bd for 3 consecutive days per week (3/7 days) and schedule B, vistusertib dosed bd for 2 consecutive days per week (2/7 days). After establishing a recommended phase II dose (RP2D), expansion cohorts in high-grade serous ovarian cancer (HGSOC) and squamous non-small-cell lung cancer (sqNSCLC) were explored in 25 and 40 patients, respectively.\ud \ud Results: \ud The dose-escalation arms comprised 22 patients with advanced solid tumours. The dose-limiting toxicities were fatigue and mucositis in schedule A and rash in schedule B. On the basis of toxicity and pharmacokinetic (PK) and pharmacodynamic (PD) evaluations, the RP2D was established as 80 mg/m2 paclitaxel with 50 mg vistusertib bd 3/7 days for 6/7 weeks. In the HGSOC expansion, RECIST and GCIG CA125 response rates were 13/25 (52%) and 16/25 (64%), respectively, with median progression-free survival (mPFS) of 5.8 months (95% CI: 3.28–18.54). The RP2D was not well tolerated in the SqNSCLC expansion, but toxicities were manageable after the daily vistusertib dose was reduced to 25 mg bd for the following 23 patients. The RECIST response rate in this group was 8/23 (35%), and the mPFS was 5.8 months (95% CI: 2.76–21.25).\ud \ud Discussion: \ud In this phase I trial, we report a highly active and well-tolerated combination of vistusertib, administered as an intermittent schedule with weekly paclitaxel, in patients with HGSOC and SqNSCLC.\ud \ud Clinical trial registration: \ud ClinicialTrials.gov identifier: CNCT02193633.

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results